24697-74-3
24697-74-3 結(jié)構(gòu)式
基本信息
益母草鹼
鹽酸益母草堿
益母草堿鹽酸鹽
鹽酸益母草堿一水合物
鹽酸益母草堿(標(biāo)準(zhǔn)品)
益母草堿, 來(lái)源于益母草
益母草堿鹽酸鹽,益母草堿
鹽酸益母草堿(益母草堿鹽酸鹽,益母草堿)
LEONURINE HYDROCHLORIDE 鹽酸益母草堿
Leonurin
Leonurine
LEONURINE HCL
Leonurine (SCM-198)
leonurine hydrochloride
4-Guanidinobutyl syringate
4-Guanidino-1-butanol syringate
Leonurine hydrochloride USP/EP/BP
Leonurine Hydrochloride Monohydrate
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
應(yīng)用領(lǐng)域
藥理藥效:1．對(duì)子宮的作用益母草堿對(duì)兔、貓、犬、豚鼠等多種動(dòng)物的子宮均呈興奮作用2．對(duì)循環(huán)系統(tǒng)的作用小劑量益母草堿對(duì)離體蛙心有增強(qiáng)收縮作用，使用大量時(shí)反呈抑制現(xiàn)象。這種抑制現(xiàn)象可能由于迷走神經(jīng)末梢興奮所致。
制備方法
18780-70-6
867-44-7
24697-74-3
一般步驟：向攪拌的4-羥基-3,5-二甲氧基苯甲酸4-氨基丁酯（5.6g，20mmol）的N,N-二甲基甲酰胺（DMF，15mL）溶液中緩慢加入S-甲基異硫脲硫酸鹽（15%水溶液，23.1g，25mmol）。將反應(yīng)混合物加熱至120℃并保持回流狀態(tài)，持續(xù)攪拌6小時(shí)。通過(guò)高效液相色譜（HPLC）監(jiān)測(cè)反應(yīng)進(jìn)程，確認(rèn)原料完全消耗后，停止加熱。在減壓條件下蒸除溶劑，將殘余物溶解于適量水中。向水溶液中分批加入碳酸氫鈉（NaHCO3，2.31g，27.5mmol），攪拌過(guò)程中有大量固體析出。通過(guò)過(guò)濾收集固體產(chǎn)物，并用適量水洗滌，干燥后得到4-胍基丁基4-羥基-3,5-二甲氧基苯甲酸酯（Leonurine，4.0g，收率65%），為白色固體。產(chǎn)物的結(jié)構(gòu)通過(guò)核磁共振氫譜（1H NMR，400MHz，以三氟乙酸為溶劑）確認(rèn)：δ7.38（s，2H），4.42（t，2H，J=6.2Hz），3.91（s，6H），3.30（t，2H，J=6.7Hz），1.89（dt，2H，J=13.3,6.5Hz），1.83-1.71（m，2H）。
參考文獻(xiàn)：
[1] Chinese Chemical Letters, 2017, vol. 28, # 6, p. 1172 - 1175
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2026/03/03 | S3890 | 鹽酸益母草堿 Leonurine | 24697-74-3 | 10mg | 1040.81元 |
| 2026/03/03 | S3890 | 鹽酸益母草堿 Leonurine | 24697-74-3 | 25mg | 2211.79元 |
| 2025/12/22 | HY-N0741A | 鹽酸益母草堿 Leonurine hydrochloride | 24697-74-3 | 5mg | 259元 |
常見(jiàn)問(wèn)題列表
Leonurine (0, 5, 10, 20, 40, 80 μM) causes diminution in lipid accumulation, cellular cholesterol content, including total cholesterol (TC), free cholesterol (FC) and cholesteryl ester (CE), and increase in apoA-I- or HDL-mediated cholesterol efflux after treatment for 24 h. Leonurine also significantly and dose-dependently increases the expressions of ABCA1 and ABCG1 at the mRNA and protein levels in human THP-1 macrophages, and such effect is involved in PPARγ. Leonurine hydrochloride (LH) shows protective effect on cell viability of HepG2 and HL-7702 cells incubated with palmitic acid (PA) of free fatty acid (FFA) for 24?h. Leonurine hydrochloride (125, 250, 500?μM) improves cellular lipid accumulation in HepG2 and HL-7702 cells via activating AMPK/SREBP1 pathway. Leonurine (5, 10, 20?μM) inhibits the expression of iNOS, COX-2, PGE2, NO, TNF-α, and IL-6 in IL-1β-induced human chondrocytes, suppresses ECM degradation in human OA chondrocytes, and blocks IL-1β-induced PI3K and Akt phosphorylation in a dose-dependent manner.
Leonurine (10 mg/kg/d, p.o.) significantly increases the expressions of PPARγ, LXRα, ABCA1 and ABCG1, and decreases both TG and TC levels in serum of mice. Leonurine hydrochloride (50, 100, 200 mg/kg) improves intracellular lipid accumulation via activating AMPK/SREBP1 pathway, enhances biochemical parameters, reduces hepatic lipoperoxide and increases antioxidant levels in mice. Leonurine (20?mg/kg, p.o.) ameliorates osteoarthritis development in mouse DMM model.